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INTRODUCTION
There is a great deal of interest in the develop-
ment of influenza vaccines with a broader pro-
tective spectrum. The best strategy for this pur-
pose may be the development of vaccines capable
of inducing a Th1 immune response with specif-
ic CTLs. There is convincing evidence that in-
fluenza specific CTLs directed against epitopes
shared by many strains are able to confer pro-
tection in murine models (Rimmelzwaan et al.,
2007), and possibly the same may be true for hu-
mans (Epstein, 2006; McMichael et al., 1986). 
Several approaches have been reported follow-
ing this strategy. Systems based on genetic im-
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munization or on the use of viral vectors have
been remarkably efficient (Berthoud et al., 2011;
Price et al., 2010; Zhou et al., 2010). However,
these methods involve sophisticated production
technology, and their safety has not yet been ful-
ly demonstrated, casting doubts on the avail-
ability of this type of vaccines in the market in
the short term.
A simpler alternative to produce a T-cell vaccine
against influenza would be to formulate the pu-
rified proteins with adjuvants capable of induc-
ing a Th1 immune response. There are several
examples that indicate that this strategy works
with conserved purified proteins of influenza
(Guo et al., 2010; Jelinek et al., 2011; Thueng-in
et al., 2010).
Based on this background, we decided to study
the immune responses induced by the recombi-
nant nucleoprotein (rNP) formulated with the
Ribi Adjuvant System (RAS) known for its abili-
ty to induce CTLs with purified proteins (Chaitra
A broad coverage influenza vaccine against multiple viral strains based on the viral nucleoprotein (NP) is a goal pur-
sued by many laboratories. If the goal is to formulate the vaccine with recombinant NP it is essential to count on ad-
juvants capable of inducing cellular immunity. This work have studied the effect of the monophosphoryl lipid A and
trehalose dimycolate, known as the Ribi Adjuvant System (RAS), in the immune response induced in mice immunized
with recombinant NP. The NP was formulated with RAS and used to immunize BALB/c mice. Immunizations with
NP-RAS increased the humoral and cellular immune responses compared to unadjuvanted NP. The predominant an-
tibody isotype was IgG2a, suggesting the development of a Th1 response. Analysis of the cytokines from mice immu-
nized with NP-RAS showed a significant increase in the production of IFN-g and a decreased production of IL-10 and
IL-4 compared to controls without RAS. These results are similar to those usually obtained using Freund’s adjuvant,
known to induce Th1 and CTL responses when co-administered with purified proteins, and suggest that a similar ap-
proach may be possible to enhance the performance of a T-cell vaccine containing NP. 
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et al., 2007). The classical adjuvant system in-
volving complete/incomplete Freund’s adjuvant
(CFA/IFA), known to induce a Th1 type immune
response (Yip et al., 1999) was selected as the gold
standard for comparison. 
The RAS is a stable oil-in-water emulsion con-
taining a non-toxic derivative of the lipopolysac-
charide (LPS) of Salmonella minnesota,
monophosphoryl lipid A (MPLA) and synthetic
trehalose dicorynomycolate (TDcM). 
MPLA is a safe and well-tolerated adjuvant ap-
proved for human use. TDcM is a low toxicity de-
rivative of the mycobacterial cord factor tre-
halose-6,6-dimycolate (TDM) (Watanabe et al.,
1999). TDM has been shown to be a potent adju-
vant that induces the Th1 and Th17 arms of the
immune response through the activation of the
Syk-CARD9 signaling pathway in APCs (Agger et
al., 2008; Davidsen et al., 2005; Khader et al., 2007;
Schoenen et al., 2010). 
Due to its significant toxicity, TDM is not appli-
cable for practical use in humans. However, the
synthetic analog trehalose-6,6-dibehenate (TDB)
is non-toxic, has the same adjuvant properties as
TDM and is currently been assayed in clinical tri-
als (Milicic et al., 2012). 
The effects of RAS on the immunogenicity of the
hemagglutinin (HA) of influenza virus, either
from viral or recombinant DNA source, has been
studied or compared with several other adjuvants
(Robuccio et al., 1995; Vanlandschoot et al., 1993).
However, to the best of our knowledge, there are
no reports on the use of MPLA, TDM or TDcM
as single adjuvants to stimulate the immune re-
sponse induced by purified NP. The results pre-
sented in this work indicate that the combination
of MPLA and a Syk-CARD9 ligand is capable of
inducing a Th1 type immunity of similar magni-
tude to that obtained with CFA/IFA. Therefore
this combination should be taken into account
in the search for adjuvants able to induce a Th1
response with purified rNP.
METHODS
Production and purification of rNP
The influenza strain A/PR/8/34 (H1N1) was pro-
vided by the World Health Organization and
grown in the allantoic cavity of embryonated hen
eggs according to standard procedures. The
cloning of the full length NP gene of A/PR/8/34
(H1N1) into the pET30a plasmid vector
(Novagen), and its expression in Escherichia coli
BL21 (DE3), as well as the purification of the rNP
by a three step chromatographic procedure have
already been described (Cargnelutti et al., 2012).
The purified rNP had an acceptable level of LPS
contamination (50 endotoxin units per 50 µg of
protein), as determined by the Limulus amebo-
cyte lysate assay.
Formulation of experimental antigens 
and immunization schedule 
RAS was purchased from Sigma-Aldrich and con-
tains monophosphoryl lipid A (MPLA) 0.5 mg,
plus trehalose dicorynomycolate (TDcM) 0.5 mg
in 2% squalene-Tween 80-water. Each vial was re-
constituted with 1 ml saline and mixed at 1:1 ra-
tio with NP in PBS and administered in mice sub-
cutaneously (1 dose =50 µl of emulsion =25 µg of
MPLA and 25 µg of TDcM). 
Freund’s complete adjuvant (CFA) was purchased
from Sigma Aldrich. Each ml contains 1 mg of
Mycobacterium tuberculosis (H37Ra, ATCC
25177); heat-killed and dried, 0.85 ml paraffin oil
and 0.15 ml mannide monooleate. 
NP in saline was mixed with an equal volume of
each adjuvant to form an emulsion. CFA was used
for initial injections and IFA for subsequent boost. 
Eight-to-nine-week-old inbred female BALB/c
mice were used in immunization experiments.
Three independent experiments were carried out
with 5 mice per group. All experiments involving
animals were approved by the Animal Care
Committee of the Medicine School from the
National University of Cuyo (IACUC number
0020398/2011). 
For priming, groups of 5 mice were subcuta-
neously vaccinated with 10 µg of NP formulated
in PBS, 10 µg of NP emulsionated with CFA or
with 10 µg of NP formulated with 50 µl of re-
constituted RAS. Three weeks later, mice were
boosted with the same formulations except that
CFA was switched to IFA. On days 0 (preimmune;
PI) and 36 post prime immunization, blood sam-
ples were collected from each mouse to evaluate
the presence of NP specific antibodies in serum.
On day 36, mice were sacrificed by cervical dis-
location and their spleens removed and processed
to recover spleen cells to prepare cultures for in
vitro determination of cytokine production.
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Analysis of humoral immune responses
The humoral immune responses induced by the
three NP formulations were evaluated by meas-
uring total specific IgG, and the specific subtypes
(IgG1 and IgG2a) by ELISA. Briefly, 96-well plates
(MaxiSorp, Nalge-Nunc International) were coat-
ed with 300 ng/well of NP in PBS and incubated
overnight at 4°C. After blocking with 5% skim
milk in PBS, plates were incubated for 1 h at 37°C
with serially diluted serum samples, followed by
three washes with the same buffer, and reacted
with goat anti-mouse IgG, IgG1 or IgG2a anti-
bodies conjugated with horse-radish peroxidase
(BD Biosciences). Plates were developed by
adding tetramethylbenzidine (TMB, Pierce-
Endogen) and incubating the plates in the dark.
The reaction was stopped using 1 N H2SO4, and
optical densities (OD) were read at 450nm with
an ELISA reader (Multiskan Ex, Thermo
Scientific). The ELISA end-point titers were ex-
pressed as the reciprocal of the highest sample
dilution that yielded an OD 2 times the mean val-
ue of control blank.
Splenocyte cultures
Spleens from vaccinated or non-vaccinated mice
were aseptically excised and used to prepare sin-
gle-cell suspensions (4 x 105 cells) in RPMI-1640
culture medium supplemented with 4 mM L-glu-
tamine, 24 mM NaHCO3, 100 units/ml of peni-
cillin, and 10% fetal calf serum. Cell viability was
>95% as determined by trypan blue exclusion.
Spleens cells were cultured in flat bottomed 96-
well microtitre plates (Greiner Bio One) and stim-
ulated with 1 µg/well of NP at 37°C in 5% CO2 for
48 h.
Cytokine ELISA assay
For detection of cytokines, culture supernatants
of spleen cells were collected after 48 h of antigen
stimulation and tested for the presence of the cy-
tokines by antigen-capture ELISA using OptEIA
Set Mouse IFN-g, IL-10 and IL-4 kits (BD
Biosciences). Negative controls were incubated
in medium alone and positive controls with medi-
um containing Concanavalin A (2.5 µg/ml). All
assays were performed in triplicate. The concen-
tration of cytokines in the culture supernatants
was calculated by using a linear-regression equa-
tion obtained from the absorbance values of the
standards.
Statistical analysis
Differences between groups were tested for sig-
nificance by Student’s unpaired t-test using
GraphPad Prism v4.00 for Windows (GraphPad
Software). A p-value less than 0,05 was consid-
ered statistically significant.
RESULTS
NP-RAS immunization elicits strong
antibody responses
The analysis of sera from inoculated mice indi-
cated that in all cases there was a specific sero-
conversion to NP. However, in the group of ani-
mals inoculated with NP formulated with RAS,
there was a significant increase in the mean titer
of total IgG anti-NP from 1,040 to 12,800 (Figure
1A). As expected, a remarkable increase in the an-
tibody titers was also observed when mice were
immunized with NP formulated with CFA/IFA,
this latter formulation being the most effective at
inducing NP-specific IgG antibodies (mean titer
46.080).
In the RAS and CFA/IFA animal groups there was
a preferential increase in the IgG2a subtype,
whereas in the control group the prevalent sub-
type was IgG1 (Figure 1B). The ratio IgG2a/IgG1
increased from 0.045 (control group) to 0.96 with
RAS formulation and from 0.045 to 0.92 with
CFA/IFA (Figure 1C). The relative values of IgG2a
and IgG1 have been used as indicators of the in-
duction of Th1 and Th2 responses, respectively
(Coffman et al., 1988). Thus, in this case,
IgG2a/IgG1 ratios were used as indicators of Th1
or Th2-biased responses induced by immuniza-
tion. The difference in the magnitude of the total
IgG titer compared to the anti-NP values of the
subtypes IgG1 and IgG2a is likely due to the use
of different anti-mouse peroxidase conjugates
(see Materials and Methods).
NP-RAS immunization induces a Th1-biased
response
To gather further information on the types of im-
mune responses induced by the different immu-
nization protocols, we used a capture ELISA to
investigate the cytokines profile secretion (IFN-g
IL-10 and IL-4) in spleen cells from NP-PBS, NP-
RAS or NP-CFA/IFA immunized mice. Re-stimu-
lation with NP induced a significantly higher pro-
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FIGURE 1 - Analysis of the humoral immune responses (A). Total Specific IgG titers induced in mice immunized
with NP-PBS, NP-RAS or NP-CFA/IFA. Values of individual animals are indicated. Horizontal lines indicate mean
values (± SEM); PI = preimmune (B) Specific IgG isotypes. (C) IgG2a/IgG1 ratio corresponding to the same groups
shown in panel A. Sera were evaluated by ELISA as indicated in the Materials and Methods section.
A B
C
FIGURE 2 - Cytokines profile. Quantitative ELISA analysis of IFN-g (A) and IL-10 (B), secreted by splenocytes of mice
immunized with NP-PBS, NP-RAS or NP-CFA/IFA upon in vitro stimulation with NP (1 µg/well). The results are pre-
sented as the mean value ± SEM. Asterisks over each bar indicate significant differences in comparison to control
groups. *, P <0.05; ns = not significant.
A B
duction of IFN-g in splenocytes from NP-RAS
(P<0.05) and NP-CFA/IFA (P<0.05) immunized
mice compared to the control group (Figure 2A),
whereas no significant differences between the 3
groups were found regarding IL-10 production
(Figure 2B). In addition, no IL-4 was detected in
any of the culture supernatants of stimulated
splenocytes (data not shown). Similar results
were reported by other groups using antigens for-
mulated with RAS (Coler et al., 2002; Ravindran
et al., 2010). Thus, the NP-RAS formulation trig-
gered a higher response of IFN-g, but similar and
low responses of IL-10 and IL-4. Taken together,
these results suggest that immunization with NP-
RAS induces a specific Th1-type immune re-
sponse in mice. These results are consistent with
the IgG2a/IgG1 ratios mentioned above.
DISCUSSION 
The development of an effective immunity against
intracellular pathogens is associated with a Th1
type immune response, dominated by the pro-
duction of IFN-g, IgG2a antibodies and CTL.
Instead, the effective control of extracellular
pathogens is associated with a Th2-type response
with production of IgG1 and production of IL-4
and IL-5 (Constant and Bottomly, 1997). One of
the major challenges in vaccinology is the devel-
opment of vaccine formulations that will induce
immune responses for the particular pathogen.
Thus, adjuvants can be a valuable tool for tailor-
ing the desired immune responses.
Recent results have indicated that the NP of in-
fluenza is an excellent candidate for developing a
broad spectrum vaccine based on induction of
cellular immunity. This has been achieved pri-
marily using genetic vaccines or vectors
(Berthoud et al., 2011; Price et al., 2010; Zhou et
al., 2010), although there have also been mean-
ingful results using purified recombinant protein
formulated with adjuvants (Guo et al., 2010;
Jelinek et al., 2011; Thueng-in et al., 2010).
The results presented in this work indicate that
NP formulated with RAS induces higher total an-
tibody titers than the unadjuvanted protein,
though lower than those induced by the protein
formulated with CFA/IFA (Figure 1A). Analysis of
IgG subtypes involved in the immune response
showed that the subtypes induced by NP-PBS
were predominantly IgG1 while NP-RAS and NP-
CFA/IFA induced a higher IgG2a/IgG1 ratio
(Figure 1B and Figure 1C), suggesting a Th1-bi-
ased response. This is in agreement with previ-
ously published works using the RAS system
(Chaitra et al., 2007).
The analysis in the cytokine production pattern in
cultured splenocytes indicated that both NP-RAS
and NP-CFA/IFA induce higher amounts of IFN-
g, and low concentrations of IL-10 and IL-4, a
hallmark of Th1-type response (Figure 2A and
Figure 2B). This is consistent with the fact that
Th1-type responses are characterized by the se-
cretion of IFN-g by T cells (Dredge et al., 2002),
something that is known to enhance IgG2 and
suppress IgG1 production (Jurado et al., 1989).
Although CTL induction was not measured, it is
known that Th1-type cellular responses and
CD8+-mediated CTL responses are generally re-
lated in their immune induction as well as in pro-
tective immunity (Sin et al., 2000).
The high titer of antibodies induced by NP-RAS
should also be taken into account. Very recently,
LaMere et al. (LaMere at al., 2011a) showed that
“systemic immunization with NP readily accel-
erated clearance of a 2009 pandemic H1N1 in-
fluenza virus isolate in an antibody-dependent
manner”. It was also demonstrated that anti-NP
IgG specifically promoted influenza virus clear-
ance in mice using a mechanism involving both
FcRs and CD8+ cells, and that anti-NP correlated
with enhanced NP-specific CD8+ T cell respons-
es (LaMere et al., 2011b). Moreover, it was re-
cently reported that an intracellular mechanism
for influenza virus neutralization in polarized ep-
ithelial cells is dependent on the transport of an
influenza neutralizing IgG by the rat neonatal Fc
receptor (Bai et al., 2011). These works strongly
suggest that the titer of antibodies induced by im-
munization with NP-RAS would also be an im-
portant attribute of a vaccine of this type. 
The two adjuvants used in this work were cho-
sen for their recognized ability to induce CTLs
with purified protein antigens (Chaitra et al.,
2007; Rao et al., 2004). It is known that immu-
nization with purified protein without adjuvant
results in the preferential presentation of the anti-
gen via MCH class II. Therefore, in the develop-
ment of strategies to induce CTL with a purified
protein one must consider the use of adjuvant
with recognized ability to induce CTLs. It has re-
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cently been shown that RAS can enhance CD8+ T
cell immune response to selected antigens and
that the CD8+ T cell response elicited by a pro-
tein formulated with RAS is equivalent to that
elicited by immunization with DNA encoding the
same protein (Chaitra et al., 2007).
We stress the following:
1) the type of immunity induced by NP-RAS re-
ported in this work;
2) the fact that MPLA is already being used in
human vaccine formulations;
3) the existence of a non-toxic derivative of TDM,
which has shown excellent performance in
pre-clinical toxicity assays (Fomsgaard et al.,
2011) and is being studied in a Phase I clini-
cal trial (Milicic et al., 2012). Taken together,
these three facts suggest that this combina-
tion of adjuvants should be seriously consid-
ered for future developments of a T-cell in-
fluenza vaccine containing NP.
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